Chimeric Antigen Receptor (CAR) T cell therapy targeting CD19 has demonstrated remarkable efficacy in treating aggressive and indolent B cell lymphomas, leading to FDA and EMA approval of three CD19-targeted CAR-T products for relapsed/refractory aggressive B cell lymphomas: axicabtagene ciloleucel (axi-cel; KTE-C19), tisagenlecleucel (tisa-cel; CTL019), and lisocabtagene maraleucel (liso-cel; JCAR017) [23,24,25]. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.